ARTES and NL join in a strategic collaboration and co-marketing alliance

ARTES, spe­cial­ized in recom-binant pro­tein pro­duc­tion and process devel­op­ment from yeast expres­sion sys­tems and the US based com­pa­ny NL Biotech-nolo­gies, own­er and spe­cial­ized in cer­tain tech-nolo­gies for pro­duc­tion of vac­cines and diag­nos­tic pro­teins start­ed a strate­gic collaboration.

With sign­ing this col­lab­o­ra­tion agree­ment the two com­pa­nies com­bine their know-how and tech­nolo­gies in yeast expres-sion, process and vac­cine devel­op­ment. The direct and notice­able aim is the mar­ket­ing of effi­cient and cost effec­tive vac­cines and diag­nos­tics pro­teins. The first prod­uct that is avail­able right from the start is a Hansenu­la poly­mor­pha derived Hepati­tis E vac­cine. Proof-of-prin­ci­ple and ani­mal stud­ies (mice and macaques) have been done and shown very good result and high immune answers.

The Hepati­tis E trans­mis­sion is a per­son-to-per­son one, nor­mal­ly trig­gered to the fecal-oral route. Infec­tions occur because of con­sump­tion of con­t­a­m­i­nat­ed water and inges­tion of raw or uncooked food – there­fore it is a dis­ease most com­mon in devel­op­ing coun­tries,“ Vitaly Gra­novskiy, man­ag­ing direc­tor of NL car­ried out. And Dr. Michael Pio­ntek, man­ag­ing direc­tor of ARTES added, ”With the Hepati­tis E process we have anoth­er reli­able and cost-effi­cient VLP-based pro­duc­tion process in our port­fo­lio. Like for HepB and avian flu, the man­u­fac­tur­ing costs for this vac­cine are low because of the effec­tive tech­nol­o­gy behind. In our mind, it should be an inter-est­ing process par­tic­u­lar for devel­op­ing countries. “

The part­ners are now look­ing for com­pa­nies to out-license the process.